An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2016
Price : $35 *
At a glance
- Drugs Mitiglinide (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ZhongdaH-Match
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2015 Planned primary completion date changed from 1 May 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.